The impact of integrating an oncology nurse practitioner into an acute care hospital emergency department: An Australian tertiary cancer centre experience.
Gillian Blanchard(Calvary Mater Newcastle Hospital), Hiren Mandaliya(Lake Macquarie Private Hospital), James Lynam, Johann Gildenhuys(Calvary Mater Newcastle Hospital), Nicholas Dafters(Calvary Mater Newcastle Hospital), Girish Mallesara(Calvary Mater Newcastle Hospital), Ina Nordman(Calvary Mater Newcastle Hospital), André van der Westhuizen(Hunter Medical Research Institute), Craig Gedye(Centre for Cancer Biology), Janine Lombard(Calvary Mater Newcastle Hospital), Antonino Bonaventura(Calvary Mater Newcastle Hospital), Fiona Day(Calvary Mater Newcastle Hospital)
Cited by 2
Related Papers
Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial
|The Lancet|2018|1.3k
Prognostic biomarkers in stage IV non-small cell lung cancer (NSCLC): neutrophil to lymphocyte ratio (NLR), lymphocyte to monocyte ratio (LMR), platelet to lymphocyte ratio (PLR) and advanced lung cancer inflammation index (ALI)
|Translational Lung Cancer Research|2019|392
Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915)
|Journal of Clinical Oncology|2022|166